Proteome Sciences PLC (GB:PRM)
LSE:PRM
Want to see GB:PRM full AI Analyst Report?
Top Page
Proteome Sciences
(LSE:PRM)
Select Model
Select Model
Rating:42Neutral
Price Target:
1.50 p
▼(-47.37% Downside)
Action:ReiteratedDate:05/02/26
The score is primarily pressured by weak financial performance, especially the strained balance sheet (high debt and deeply negative equity) and ongoing losses. Technicals are mixed with only a modest near-term rebound and negative MACD, while valuation is constrained by negative earnings and no provided dividend yield.
Positive Factors
Specialized proteomics capability
Proteome Sciences' core technical capabilities in proteomics and mass spectrometry are highly specialized, creating durable scientific barriers to entry. These capabilities align with drug discovery needs, supporting repeat engagements, technical differentiation, and long-term client reliance on expert analytical services.
Negative Factors
Strained balance sheet
Debt materially exceeds assets and equity is deeply negative, indicating a capital structure under severe strain. This raises refinancing and solvency risk, limits financial flexibility for investment or working capital, and increases the probability of shareholder dilution or covenant constraints.
Read all positive and negative factors
Positive Factors
Negative Factors
Specialized proteomics capability
Proteome Sciences' core technical capabilities in proteomics and mass spectrometry are highly specialized, creating durable scientific barriers to entry. These capabilities align with drug discovery needs, supporting repeat engagements, technical differentiation, and long-term client reliance on expert analytical services.
Read all positive factors
Proteome Sciences (PRM) vs. iShares MSCI United Kingdom ETF (EWC)
Market Cap
£5.26M
Dividend YieldN/A
Average Volume (3M)476.64K
Price to Earnings (P/E)―
Beta (1Y)0.41
Revenue Growth-23.14%
EPS Growth9.57%
CountryUK
Employees36
SectorHealthcare
Sector Strength45
IndustryMedical - Diagnostics & Research
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding350,724,900
10 Day Avg. Volume209,671
30 Day Avg. Volume476,642
Financial Highlights & Ratios
PEG Ratio0.25
Price to Book (P/B)-0.77
Price to Sales (P/S)1.96
P/FCF Ratio-51.61
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Proteome Sciences Business Overview & Revenue Model
Company Description
Proteome Sciences plc provides contract research services for the identification, validation, and application of protein biomarkers in the United States, the United Kingdom, and European Union. The company offers SysQuant provides comprehensive an...
How the Company Makes Money
Proteome Sciences makes money primarily by selling proteomics and mass spectrometry–based contract research and analytical services. Revenue is generated when customers (typically pharma/biotech companies and research institutions) pay for project...
Proteome Sciences Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
12
Very Negative
Cash Flow
26
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 3.76M | 4.89M | 5.03M | 7.78M | 5.12M |
| Gross Profit | -1.01M | -167.00K | 1.16M | 4.77M | 2.96M |
| EBITDA | -1.74M | -1.44M | -986.00K | 1.89M | 725.00K |
| Net Income | -3.06M | -3.41M | -2.44M | 1.32M | 72.00K |
Balance Sheet | |||||
| Total Assets | 8.26M | 9.21M | 11.46M | 12.43M | 10.04M |
| Cash, Cash Equivalents and Short-Term Investments | 781.00K | 1.13M | 2.03M | 3.99M | 2.39M |
| Total Debt | 15.77M | 14.52M | 13.47M | 11.91M | 11.69M |
| Total Liabilities | 17.79M | 15.72M | 14.52M | 13.28M | 12.82M |
| Stockholders Equity | -9.53M | -6.52M | -3.07M | -843.00K | -2.77M |
Cash Flow | |||||
| Free Cash Flow | -143.00K | -1.05M | -718.00K | 2.14B | 8.80B |
| Operating Cash Flow | -46.00K | -826.00K | -481.00K | 3.88B | 10.52B |
| Investing Cash Flow | -97.00K | -224.00K | -424.00K | -21.67B | 4.27B |
| Financing Cash Flow | -204.00K | 151.00K | -1.06M | -209.00K | -400.00K |
Proteome Sciences Technical Analysis
Negative
2.85
Price Trends
1.71
Negative
2.09
Negative
2.33
Negative
Market Momentum
-0.08
Positive
19.34
Positive
57.25
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:PRM, the sentiment is Negative. The current price of 2.85 is above the 20-day moving average (MA) of 1.57, above the 50-day MA of 1.71, and above the 200-day MA of 2.33, indicating a bearish trend. The MACD of -0.08 indicates Positive momentum. The RSI at 19.34 is Positive, neither overbought nor oversold. The STOCH value of 57.25 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for GB:PRM.
Proteome Sciences Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
58 Neutral | £7.19M | -0.39 | -122.54% | ― | -57.03% | -15.71% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | £10.23M | -1.31 | -104.73% | ― | 29.64% | 28.51% | |
47 Neutral | £14.85M | -0.76 | -153.92% | ― | 65.60% | 74.84% | |
43 Neutral | £5.06M | -2.61 | -2.42% | ― | 102.28% | 95.58% | |
42 Neutral | £5.26M | -2.41 | 44.15% | ― | -23.14% | 9.57% | |
40 Underperform | £9.04M | -0.47 | -181.41% | ― | 12.12% | 54.24% |
* Healthcare Sector Average
GB:PRM
Proteome Sciences
1.68
-1.06
-38.69%
GB:CLBX
ANGLE plc
0.90
-7.50
-89.29%
GB:GDR
Genedrive
0.95
-0.53
-35.90%
GB:OPTI
OptiBiotix Health
5.10
-14.90
-74.50%
GB:VRCI
Verici Dx Plc
0.48
-1.15
-70.46%
GB:GENI
GENinCode UK Ltd.
1.23
-0.29
-19.41%
Proteome Sciences Corporate Events
Business Operations and StrategyExecutive/Board ChangesFinancial DisclosuresPrivate Placements and FinancingProduct-Related AnnouncementsShareholder Meetings
Proteome Sciences Bets on Services Growth and New Tags After TMT Slump
Neutral
Apr 15, 2026
Proteome Sciences reported a sharp decline in 2025 group revenue to £3.76m from £4.89m, as TMT reagent sales and royalties nearly halved due to deep U.S. National Institutes of Health funding cuts, though proteomic services revenue more ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.